Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Go back to Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 80.88 +1.17 (1.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $79.71 | 52 Week High | $10.00 | |||
| Open | $80.03 | 52 Week Low | $3.22 | |||
| Day High | $82.31 | P/E | N/A | |||
| Day Low | $79.22 | EPS | $-0.46 | |||
| Volume | 471,178 | |||||
